Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 371, Issue 2, 2008, Pages 197-202

  Kim, Sang Wan ^a,b   Choi, Ok Kyung ^b   Chang, Mee Soo ^b   Shin, Chan Soo ^a   Park, Kyong Soo ^a   Kim, Seong Yeon ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Nerve growth factor; PC12 cells; Pheochromocytoma; PPAR ; Thiazolidinediones

Indexed keywords

CASPASE 3; CATECHOLAMINE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; NERVE GROWTH FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ANIMAL CELL; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE FIBER GROWTH; NONHUMAN; NUDE MOUSE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADRENAL GLAND NEOPLASMS; ANIMALS; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL PROLIFERATION; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; HUMANS; KI-67 ANTIGEN; MICE; NERVE GROWTH FACTOR; NEURONS; PC12 CELLS; PHEOCHROMOCYTOMA; PPAR GAMMA; RATS; THIAZOLIDINEDIONES;

RATTUS;

EID: 43049156397     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.035     Document Type: Article

References (25)

1. Pacak K., Chrousos G.P., Koch C.A., Lenders J.W.M., and Eisenhofer G. Pheochoromocytoma: progress in diagnosis, therapy, and genetics. In: Margioris A.N., and Chrousos G.P. (Eds). Adrenal Disorders (2001), Humana Press, Totowa 379-414
2. Hevener A.L., He W., Barak Y., Le J., Bandyopadhyay G., Olson P., Wilkes J., Evans R.M., and Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9 (2003) 1491-1497
3. Walczak R., and Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J. Lipid Res. 43 (2002) 177-186
4. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., Shintaku P., Said J.W., Heber D., and Koeffler H.P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA 95 (1998) 8806-8811
5. Keshamouni V.G., Reddy R.C., Arenberg D.A., Joel B., Thannickal V.J., Kalemkerian G.P., and Standiford T.J. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23 (2004) 100-108
6. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S., Oh W., Demetri G., Figg W.D., Zhou X.P., Eng C., Spiegelman B.M., and Kantoff P.W. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. USA 97 (2000) 10990-10995
7. Chung S.H., Onoda N., Ishikawa T., Ogisawa K., Takenaka C., Yano Y., Hato F., and Hirakawa K. Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn. J. Cancer Res. 93 (2002) 1358-1365
8. Ferruzzi P., Ceni E., Tarocchi M., Grappone C., Milani S., Galli A., Fiorelli G., Serio M., and Mannelli M. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J. Clin. Endocrinol. Metab. 90 (2005) 1332-1339
9. Betz M.J., Shapiro I., Fassnacht M., Hahner S., Reincke M., and Beuschlein F. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J. Clin. Endocrinol. Metab. 90 (2005) 3886-3896
10. Heaney A.P., Fernando M., Yong W.H., and Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 8 (2002) 1281-1287
11. Fu M., Zhang J., Lin Yg Y., Zhu X., Willson T.M., and Chen Y.E. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 294 (2002) 597-601
12. Cowen D., Troncoso P., Khoo V.S., Zagars G.K., von Eschenbach A.C., Meistrich M.L., and Pollack A. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin. Cancer Res. 8 (2002) 1148-1154
13. Brockman J.A., Gupta R.A., and Dubois R.N. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115 (1998) 1049-1055
14. Galli A., Ceni E., Crabb D.W., Mello T., Salzano R., Grappone C., Milani S., Surrenti E., Surrenti C., and Casini A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 53 (2004) 1688-1697
15. Rumi M.A., Ishihara S., Kadowaki Y., Ortega-Cava C.F., Kazumori H., Kawashima K., Yoshino N., Yuki T., Ishimura N., and Kinoshita Y. Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 9 (2004) 1113-1123
16. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., and Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11 (1997) 1464-1478
17. Fang F., Orend G., Watanabe N., Hunter T., and Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271 (1996) 499-502
18. Itami A., Watanabe G., Shimada Y., Hashimoto Y., Kawamura J., Kato M., Hosotani R., and Imamura M. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int. J. Cancer 94 (2001) 370-376
19. Toyota M., Miyazaki Y., Kitamura S., Nagasawa Y., Kiyohara T., Shinomura Y., and Matsuzawa Y. Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci. 70 (2002) 1565-1575
20. Fuenzalida K.M., Aguilera M.C., Piderit D.G., Ramos P.C., Contador D., Quinones V., Rigotti A., Bronfman F.C., and Bronfman M. Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells. J. Biol. Chem. 280 (2005) 9604-9609
21. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 530 (2006) 70-80
22. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696
23. Satoh T., Furuta K., Suzuki M., and Watanabe Y. Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells. Biochem. Biophys. Res. Commun. 258 (1999) 50-53
24. Elder E.E., Xu D., Hoog A., Enberg U., Hou M., Pisa P., Gruber A., Larsson C., and Backdahl M. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod. Pathol. 16 (2003) 246-255
25. Mastronardi L., Guiducci A., and Puzzilli F. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1 (2001) 12